AIGH Capital Management LLC Acquires 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

AIGH Capital Management LLC raised its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 17.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,574,846 shares of the company’s stock after purchasing an additional 389,192 shares during the quarter. Xeris Biopharma accounts for about 2.7% of AIGH Capital Management LLC’s portfolio, making the stock its 15th largest position. AIGH Capital Management LLC owned about 1.73% of Xeris Biopharma worth $8,729,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in XERS. China Universal Asset Management Co. Ltd. lifted its stake in shares of Xeris Biopharma by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock valued at $107,000 after purchasing an additional 2,954 shares during the last quarter. GPS Wealth Strategies Group LLC boosted its stake in Xeris Biopharma by 6.2% during the fourth quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock worth $227,000 after buying an additional 3,900 shares during the period. Janney Montgomery Scott LLC increased its position in Xeris Biopharma by 31.4% during the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock valued at $78,000 after acquiring an additional 5,500 shares during the last quarter. Prudential Financial Inc. raised its stake in shares of Xeris Biopharma by 23.4% in the fourth quarter. Prudential Financial Inc. now owns 36,945 shares of the company’s stock valued at $125,000 after acquiring an additional 7,000 shares during the period. Finally, Goldstein Advisors LLC lifted its holdings in shares of Xeris Biopharma by 24.2% in the 4th quarter. Goldstein Advisors LLC now owns 37,800 shares of the company’s stock worth $128,000 after acquiring an additional 7,375 shares during the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Trading Down 0.9 %

Shares of XERS stock opened at $5.58 on Friday. The stock has a market capitalization of $858.99 million, a price-to-earnings ratio of -12.40 and a beta of 2.32. Xeris Biopharma Holdings, Inc. has a twelve month low of $1.69 and a twelve month high of $6.07. The stock has a fifty day simple moving average of $4.13 and a two-hundred day simple moving average of $3.52.

Analysts Set New Price Targets

XERS has been the topic of a number of recent analyst reports. Craig Hallum increased their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research report on Friday, March 7th. HC Wainwright reissued a “buy” rating and set a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Jefferies Financial Group reiterated a “buy” rating and set a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Finally, Leerink Partners upped their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $6.10.

Insider Buying and Selling

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the sale, the insider now owns 1,353,510 shares of the company’s stock, valued at approximately $7,349,559.30. This trade represents a 2.87 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.56% of the stock is owned by insiders.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.